Ana Herrero

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

Carmen Balañá, María Ángeles Vaz Salgado, Juan Manuel Sepúlveda-Sánchez et al. · Neuro-Oncology · 2020 · 107 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

Jean‐Emmanuel Kurtz, Éric Pujade-Lauraine, Ana Oaknin et al. · Journal of Clinical Oncology · 2023 · 103 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Genetic and biochemical markers in patients with Alzheimer's disease support a concerted systemic iron homeostasis dysregulation

Ângela C. Crespo, Bruno Silva, Liliana Marques et al. · Neurobiology of Aging · 2013 · 81 citations

Medicine, Neurology, Neuroscience +16

SEOM clinical guidelines in hereditary breast and ovarian cancer (2019)

Santiago González-Santiago, Teresa Ramón y Cajal, Elena Aguirre et al. · Clinical & Translational Oncology · 2019 · 72 citations · Full text

Life Sciences, Genetics, Oncology +17

Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study.

Laura García‐Estévez, J. Cuevas, Antonio Antón et al. · PubMed · 2003 · 70 citations

Medicine, Oncology, Pharmacology +17